Stock analysts at Royal Bank Of Canada assumed coverage on shares of TESARO, Inc. (NASDAQ:TSRO) in a research report issued on Thursday, The Fly reports. The firm set a “sector perform” rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued research reports about the stock. Credit Suisse Group set a $198.00 price objective on shares of TESARO and gave the stock a “buy” rating in a report on Monday, June 5th. Cann reiterated a “buy” rating and issued a $199.00 price objective on shares of TESARO in a report on Monday, June 5th. Oppenheimer Holdings, Inc. set a $199.00 price objective on shares of TESARO and gave the stock a “buy” rating in a report on Sunday, June 4th. Bank of America Corporation reiterated a “buy” rating and issued a $154.00 price objective on shares of TESARO in a report on Tuesday, June 20th. Finally, Gabelli initiated coverage on shares of TESARO in a report on Friday, July 7th. They issued a “buy” rating and a $175.00 price objective on the stock. One analyst has rated the stock with a sell rating, eleven have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $175.15.

Shares of TESARO (NASDAQ TSRO) traded down 0.34% during trading on Thursday, hitting $115.24. The company’s stock had a trading volume of 620,800 shares. TESARO has a 52 week low of $93.93 and a 52 week high of $192.94. The firm’s 50 day moving average price is $122.82 and its 200-day moving average price is $141.29. The company’s market cap is $6.24 billion.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm had revenue of $29.50 million during the quarter, compared to analyst estimates of $18.61 million. During the same quarter in the prior year, the firm earned ($1.28) EPS. The business’s quarterly revenue was down 17.6% compared to the same quarter last year. On average, analysts predict that TESARO will post ($8.67) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “TESARO, Inc. (TSRO) Now Covered by Analysts at Royal Bank Of Canada” was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/14/tesaro-inc-tsro-now-covered-by-analysts-at-royal-bank-of-canada.html.

In related news, VP Grant C. Bogle sold 14,167 shares of the business’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Edward C. English sold 10,862 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the sale, the vice president now directly owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 25,100 shares of company stock valued at $3,387,465. Insiders own 40.50% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Vident Investment Advisory LLC bought a new stake in shares of TESARO during the 1st quarter valued at about $351,000. Botty Investors LLC bought a new stake in shares of TESARO during the 2nd quarter valued at about $140,000. Meeder Asset Management Inc. bought a new stake in shares of TESARO during the 1st quarter valued at about $177,000. Nordea Investment Management AB bought a new stake in shares of TESARO during the 2nd quarter valued at about $167,000. Finally, Oppenheimer Asset Management Inc. grew its position in shares of TESARO by 3,042.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,430 shares during the last quarter.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

The Fly

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.